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Introduction: The emergence of hormone therapy resistance, despite continued expression of the estrogen receptor
(ER), is a major challenge to curing breast cancer. Recent clinical studies suggest that epigenetic modulation by
histone deacetylase (HDAC) inhibitors reverses hormone therapy resistance. However, little is known about epigenetic
modulation of the ER during acquired hormone resistance. Our recent phase II study demonstrated that HDAC
inhibitors re-sensitize hormone therapy-resistant tumors to the anti-estrogen tamoxifen. In this study, we sought to
understand the mechanism behind the efficacy of this combination.
Methods: We generated cell lines resistant to tamoxifen, named TAMRM and TAMRT, by continuous exposure of
ER-positive MCF7 and T47D cells, respectively to 4-hydroxy tamoxifen for over 12 months. HDAC inhibition, along with
pharmacological and genetic manipulation of key survival pathways, including ER and Bcl-2, were used to characterize
these resistant models.
Results: The TAMRM cells displayed decreased sensitivity to tamoxifen, fulvestrant and estrogen deprivation. Consistent
with previous models, ER expression was retained and the gene harbored no mutations. Compared to parental MCF7
cells, ER expression in TAMRM was elevated, while progesterone receptor (PGR) was lost. Sensitivity of ER to ligands was
greatly reduced and classic ER response genes were suppressed. This model conveyed tamoxifen resistance through
transcriptional upregulation of Bcl-2 and c-Myc, and downregulation of the cell cycle checkpoint protein p21,
manifesting in accelerated growth and reduced cell death. Similar to TAMRM cells, the TAMRT cell line exhibited
substantially decreased tamoxifen sensitivity, increased ER and Bcl-2 expression and significantly reduced PGR expression.
Treatment with HDAC inhibitors reversed the altered transcriptional events and reestablished the sensitivity of the ER to
tamoxifen resulting in substantial Bcl-2 downregulation, growth arrest and apoptosis. Selective inhibition of Bcl-2 mirrored
these effects in presence of an HDAC inhibitor.
Conclusions: Our model implicates elevated ER and Bcl-2 as key drivers of anti-estrogen resistance, which can be
reversed by epigenetic modulation through HDAC inhibition.* Correspondence: pmunster@medicine.ucsf.edu
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About 70% of all breast cancers express the estrogen re-
ceptor (ER). Commonly used therapies to treat these can-
cers either target the ER directly through selective ER
modulators and downregulators (SERMs and SERDs); or
diminish endogenous estrogen levels via ovarian ablation
or the use of aromatase inhibitors. However, the emer-
gence of hormone therapy resistance remains a significant
hurdle, as almost 40% of women with metastatic, ER-
positive disease progress despite the initial efficacy [1].
The evolution of hormone therapy resistance appears
to involve multiple diverging mechanisms. Thus, under-
standing the complexity of resistance is crucial to iden-
tify novel targets and select biomarkers. Mechanisms
associated with acquired resistance to hormone therapy
include decrease or loss of ER expression or function;
variation in ER-associated transcription factor recruit-
ment; genetic mutations and epigenetic modulations;
elevation and activation of the HER2 pathway; mutations
and modulation of the PI3K/mTOR pathway; upregula-
tion of cyclin D1 and loss of p16; or activation of Myc
pathway [1-3].
Emerging data link epigenetic changes affecting ER
expression and its target gene promoters, to acquired
resistance [4,5]. Histone deacetylases (HDAC) and trans-
ferases (HAT) are chromatin modifiers that lead to epi-
genetic changes in the cell and have been implicated in
the development of drug resistance in several cancers
including breast. These enzymes regulate acetylation of
histone and non-histone proteins, and thereby control
key cellular processes including cell cycle progression,
proliferation, survival, DNA repair and differentiation
[6,7]. There have been several studies evaluating the role
of HDAC inhibitors in both ER-positive and -negative
settings [8,9]. However, in clinical studies, HDAC inhibi-
tors have failed to show considerable anti-tumor activity
as single agents in breast tumors [10]. As such, HDAC
inhibitors have become an attractive constituent of com-
bination regimens, including hormone therapy for the
treatment of breast cancer [1].
Recently, we reported the first clinical study evaluating
the co-administration of an HDAC inhibitor (vorinostat)
with an anti-estrogen (tamoxifen) in advanced breast
cancer patients. Clinical benefit was achieved in 40% of pa-
tients (19% objective response and 21% stable disease for
more than 6 months) despite progression on multiple prior
anti-estrogen therapies and chemotherapy [11]. Subse-
quently, the HDAC inhibitor, entinostat, was shown to re-
verse hormone therapy resistance when combined with the
aromatase inhibitor exemestane [12]. Thus, HDAC inhi-
bition appears to reestablish sensitivity to anti-estrogens in
a subset of resistant tumors. However, the ability to identify
these responding tumors is limited by the poor under-
standing of the mechanism that underlies its effectiveness.In the current study, we thus sought to characterize
the mechanism underpinning the effectiveness of inhi-
biting HDAC and ER activity in anti-estrogen-resistant
breast cancer. We developed novel breast cancer cell
lines that model acquired tamoxifen-resistant breast cancer
(tamoxifen-resistant cells derived from MCF7 (TAMRM)
and tamoxifen-resistant cells derived from T47D (TAMRT)).
These models exhibit elevated ER, Bcl-2, and c-Myc
expression and reduced p21 expression, which together
result in enhanced cell proliferation and reduced sus-
ceptibility to cell death. Although ER is overexpressed,
ligand-mediated ER transactivation is substantially re-
duced. HDAC inhibition is sufficient to reverse ER, c-Myc
and p21 expression and inhibit proliferation. However,
combined HDAC and ER inhibition is required for signifi-
cant Bcl-2 downregulation and apoptotic induction. Thus,
tumors that exhibit apoptotic resistance and impaired pro-
liferation checkpoints may be candidates for combined
HDAC and ER inhibition.
Materials and methods
Chemicals, antibodies and drugs
4-hydroxy tamoxifen (Tam) was purchased from Calbiochem
(San Diego, CA, USA). Valproic acid and fulvestrant (Ful)
were purchased from Sigma-Aldrich (St. Louis, MO, USA).
Entinostat and ABT.263 were purchased from Selleck
Chemicals LLC (Houston, TX, USA). PCI-24781 (PCI),
vorinostat and panobinostat were gifts from Pharmacyclics
Inc. (Sunnyvale, CA, USA), Aton Pharma Inc. and Novartis
International (Basel, Switzerland), respectively. Antibodies
against ER-α and p21 were purchased from Santa Cruz
Biotechnology, Inc. (Santa Cruz, CA, USA). Antibodies
against progesterone receptor (PGR), Bim, Bak, Bax, Bok,
Bid, c-Myc and PARP were purchased from Cell Signaling
Technology (Danvers, MA, USA). GAPDH and beta-actin
antibodies were purchased from EMD Millipore (Billerica,
MA, USA) and Abcam (Cambridge, MA, USA).
Cell culture
MCF7 and T47D cells were purchased from American
Type Culture Collection (Manassas, VA, USA) and main-
tained in Dulbecco’s modified Eagle’s medium (DMEM)
(Thermo Fisher Scientific, Waltham, MA, USA) supple-
mented with 10% fetal bovine serum (Sigma-Aldrich),
2 mM glutamine, 50 unit/mL penicillin and 50 μg/ml
streptomycin (Thermo Fisher Scientific). The above media
was used for all experiments unless specified. The Tam-
resistant cell lines TAMRM and TAMRT were generated
by continuous exposure of MCF7 and T47D cells to in-
creasing doses of Tam up to 10 μM and 6 μM, respec-
tively, in complete DMEM and thereafter maintaining
them in presence of 10 μM and 6 μM Tam. Cells were
maintained at 37°C in a humidified atmosphere containing
5% CO2. Resistant cell lines were passaged for a maximum
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Colony-forming assay
Two hundred cells per well were seeded in a 12-well
plate and treated with vehicle (DMSO), 200 nM PCI (P),
10 μM Tam (T) or the PCI-24781 and 4-hydroxy tam-
oxifen (PT) combination for 72 hours after which media
with drugs were replaced with fresh media. Fourteen
days later, cells were fixed with methanol, stained with
2% crystal violet and colonies were counted.
Cell proliferation and viability assays
Proliferation assays were conducted using CellTiter 96
Cell Proliferation Assay (MTS) solution following the
manufacturer’s protocol (Promega, Madison, WI, USA).
BrdU incorporation assay was conducted using the assay
kit from Cell Signaling Technology following the manu-
facturer’s recommendation. Viability was assayed by try-
pan blue dye exclusion, as previously described [13].
Cell cycle analysis by flow cytometry
Cells were stained with propidium iodide (PI) using the
Abcam kit (ab139418) according to the provided proto-
col. Briefly, cells were harvested, washed in ice-cold
phosphate-buffered saline (PBS) and fixed in 70% etha-
nol for 30 minutes at 4°C. After two PBS washes, cells
were treated with RNase A for 15 minutes at 37°C,
stained with 5 μg/mL PI in PBS and assayed with a
FACS Calibur (BD Biosciences, San Jose, CA, USA) flow
cytometer using Cell Quest software. The cell cycle
distribution was analyzed using BD CellQuest™ Pro
Analysis software (BD Biosciences).
Luciferase reporter gene assay
Cells were trypsinized and collected in phenol red-free
media supplemented with 5% charcoal dextran stripped
serum (CDSS) (Invitrogen, Carlsbad, CA, USA) and
transfected with the ERE-tk-109-luciferase plasmid using
Lipofectamine™ LTX (Invitrogen). Transfected cells were
incubated in 96-well plates for 5 hours, after which
ligands prepared in serum-free media were added to the
cells and incubated for 20 hours. Media was then dis-
carded, and 50 μl of Promega bright-glo luciferase sub-
strate dissolved in lysis buffer was added to the cells
before recording luminescence using a Veritas Micro-
plate Luminometer (Promega).
Western immunoblotting
Proteins were extracted in lysis buffer (0.1% SDS, 1%
Triton X-100, 50 mM Tris-HCl pH 7.4, 150 mM NaCl,
10% glycerol, 1X Halt protease and phosphatase inhi-
bitor cocktail (Thermo Fisher Scientific)), separated on
4 to 12% Bis-Tris Nu-PAGE gels and transferred toImmobilon-P polyvinylidene fluoride (PVDF) micro-
porous membrane (EMD Millipore) at 100 V for 1 hour.
Membranes were blocked using 5% (w/v) non-fat dry
milk in Tris-buffered saline containing 0.1% Tween 20
(TBST) and subsequently probed with primary antibodies
followed by horseradish peroxidase-linked secondary anti-
bodies and visualized using the ECL Plus Western Blotting
Detection System (GE Healthcare, Little Chalfont, UK).
siRNA depletion
Small interfering RNA (siRNA) duplexes for ESR1
(ID# 42835) and BCL-2 (ID# 214532) mRNA depletion
were purchased from Applied Biosystems (Carlsbad,
CA, USA). Cells were transfected with siRNA duplexes
by nucleofection using the Nucleofector Transfection
Kit according to the manufacturer’s protocol (Amaxa,
Gaithersburg, MD, USA). The silencer negative control
#2 from Applied Biosystems was used as a transfection
control and referred to as scramble (Sc).
mRNA expression analysis
Total RNA was purified from cells using the Qiagen
RNeasy Kit (Valencia, CA, USA). cDNA was generated
using the iScript cDNA synthesis kit (Bio-Rad Labs Inc.,
Hercules, CA, USA). Taqman expression assays for ESR1
(ID# Hs00174860_m1), PGR (Hs01556702_m1), TFF1
(ID# Hs00907239_m1), BCL-2 (ID# Hs00608023_m1),
CDH1 (ID# Hs01023894_m1), GREB1 (ID# Hs0053
6409_m1), H.CTSD (ID# Hs00157205_m1), TRIM25 (ID#
Hs01116121_m1), and c-MYC (ID# Hs00153408_m1)
were purchased from Applied Biosystems. Expression was
determined using an ABI 7900 HT Thermocycler (Applied
Biosystems) and normalized to b-glucuronidase (h.Gus).
In vivo studies
Animal studies were conducted according to a UCSF
Laboratory Animal Resource Center (LARC) protocol
(AN090303). This protocol was approved by the UCSF
Institutional Animal Care and Use Committee (IACUC)
accredited by Association for Assessment and Accredi-
tation of Laboratory Animal Care International (#001084).
Four- to six-week-old female nude athymic Crl;NU(NCr)-
Foxn1nu mice (Charles River Laboratories, Wilmington,
MA, USA) were used for the study. MCF7 and TAMRM
cells were implanted subcutaneously following subcutane-
ous implantation of a 60-day release estradiol (E2) pellet.
For each cell line, two cohorts of five mice received sub-
cutaneous administrations, 5/7 days, with either 50 μL of
10 mg/mL tamoxifen citrate in peanut oil or vehicle. At
the conclusion of the study, tumors were harvested. Pro-
tein was extracted from tumors using a mortar and pestle
in the presence of liquid nitrogen. Ground tumors were
incubated with cell lysis buffer (0.1% SDS, 1% Triton
X-100, 50 mM Tris-HCl pH 7.4, 150 mM NaCl, 10%
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tor cocktail), syringe passaged, and lysate cleared by
centrifugation.
Statistical analysis
Data are expressed as averages, with the standard error
of mean (±S.E.M.) indicated. A two-sided non-paired
Student’s t test was used to determine differences bet-
ween two groups with P <0.05 considered statistically
significant.
Results
Tamoxifen-resistant cells display accelerated growth rate
and decreased sensitivity to fulvestrant
Previous studies have shown that continuous exposure
of ER-positive breast cancer cells to Tam results in sup-
pression of classical ER genomic signaling activity with-
out loss of ER expression [14-17]. This suggests a direct
role for the ER in driving resistance [18]. To mimic the
emergence of hormone therapy resistance, we generated
in vitro Tam-resistant cell lines TAMRM and TAMRT
(see Materials and methods). Resistance to Tam was
reflected in TAMRM and MCF7 total cell counts, re-
corded over time with and without 10 μM Tam treatment
and expressed as fold increase over time compared to
baseline (0 h) (Figure 1A). In the absence of Tam,
TAMRM cells grew considerably faster than parental
MCF7 cells, as illustrated by the doubling times (Dts,
21.5 versus 33.1 hours). Treatment with 10 μM Tam
arrested MCF7 cell growth. However, with the same con-
centration of Tam, TAMRM cell growth was only mod-
estly reduced (23.9% reduction in doubling time).
Consistent with elevated proliferation rate, TAMRM cells
exhibited greater BrdU incorporation compared to MCF7
cells, both in the absence and presence of Tam (Fig-
ure 1B). To test whether TAMRM cells had altered sensi-
tivity to estrogen and the anti-estrogen fulvestrant, cells
were incubated for 48 hours in estrogen-free media and
then treated with vehicle (C), E2 1 nM, Tam 1 μM or Ful
0.1 μM. As expected, E2 stimulated the growth of MCF7
cells, whereas the absence of E2 or the presence of anti-
estrogens Tam or Ful inhibited growth (Figure 1C). In
contrast, the presence or absence of E2 or Tam did not
significantly affect TAMRM cell growth. Furthermore,
treatment with Ful only partially inhibited TAMRM cell
growth. Thus, consistent with previous reports, develop-
ment of Tam resistance in TAMRM cells resulted only in
partial cross-resistance to Ful [19,20]. Treatment with in-
creasing Ful concentrations for 24 hours depleted ER
protein in both cell lines (Figure 1D). However, compar-
able doses of Ful up to 500 nM resulted in substantially
more ER loss in MCF7 compared to TAMRM cells,
consistent with the growth assay. This suggested the
TAMRM cells were less sensitive to Ful inhibitioncompared to MCF7 cells. The increased proliferation and
decreased sensitivity of TAMRM cells to Tam was also
observed in in vivo tumor xenografts (Figure 1E). Similar
to cells grown in vitro, TAMRM-derived tumors did not
require E2 for growth, unlike MCF7 cells (Figure S1 in
Additional file 1). The relative proliferation of TAMRT
cells as compared to T47D cells, treated with increasing
Tam doses in complete media for 72 hours demonstrates
the Tam resistance of this TAMRT cell line (Figure 1F).
Tamoxifen-resistant cells display altered gene expression
profile
Several mechanisms of resistance have been attributed to
the development of acquired hormone resistance, includ-
ing altered expression of key proteins regulating prolifera-
tion and death. Consistent with prior preclinical models
and in the clinic, ER expression was maintained in both
our tamoxifen-resistant cell lines [21,22]. Evaluation of ER
expression in TAMRM cells revealed that both mRNA
(ESR1) and protein were higher compared to MCF7 cells,
4- and 2-fold, respectively (Figure 2A and B).
To determine whether increased ER expression affected
its activity, ER target gene expression was examined. Des-
pite the elevated levels of ER in both resistant models, ex-
pression of classic ER response genes (for example PGR
and TFF1) were substantially reduced (Figure 2A and E). It
has been previously shown that the pro-growth and sur-
vival signals mediated by estrogen signaling are in part
through the regulation of c-Myc, p21 and Bcl-2 expression
[23-25]. Consistent with the higher proliferation capacity of
TAMRM cells, the major cell cycle checkpoint protein
p21 was suppressed (approximately 90%) (Figure 2B)
and c-Myc substantially elevated (approximately 300%)
compared to MCF7 cells. Furthermore, Bcl-2 expression
increased nearly 600%. Consistent with these in vitro
findings, the TAMRM xenografts expressed higher Bcl-2
and c-Myc proteins and lower p21 protein compared to the
MCF7 xenografts. However there was no significant in-
crease in ER protein in the TAMRM xenografts (Figure 2C).
Comparing the basal level of proteins in the TAMRT cells,
we found that these resistant cells also displayed higher ER
and Bcl-2 proteins and substantially reduced PGR protein
as compared to T47D parental cells (Figure 2D). Basal
mRNA levels of BCL-2 and PGR corresponded with the
proteins, but ESR1 mRNA was not elevated in the TAMRT-
resistant cells although ER protein was found to be elevated
(Figure 2E). This suggests that the relative mechanisms
leading to ER protein upregulation likely differ in the two
resistant models.
ER-mediated transactivation and ligand sensitivity is
altered in TAMRM cells
External stimulation by E2 results in ER dimerization
and activation of estrogen response elements (EREs) or
Figure 1 Tamoxifen-resistant cells display accelerated growth rate and decreased sensitivity to fulvestrant. (A) Cells were grown in
complete media in the presence or absence of 10 μM 4-hydroxy tamoxifen (Tam) for 24, 48, 72 and 144 hours, and (C) in estradiol (E2)-free media
for 48 and 96 hours and supplemented with vehicle (C) (DMSO), 1 nM E2, 1 μM Tam and 0.1 μM fulvestrant (Ful). Fold increase in cell counts
normalized to zero hour counts of respective cell lines are represented. (B) Cells were grown in the presence of DMSO or 10 μM Tam in complete
media. BrdU substrate was added 48 hours after drug treatment and assayed after 24 hours. (D) Cells were treated with increasing Ful concentrations
for 24 hours and evaluated for estrogen receptor (ER) protein. Presented is a representative western blot. The bar graph represents densitometry
analysis of the ER/GAPDH ratio, normalized to the respective untreated controls, from two independent experiments. (E) Tumor volumes of MCF7 and
tamoxifen-resistant cells derived from MCF7 (TAMRM) cell mouse xenografts treated over time with vehicle or Tam are represented. (F) T47D and
tamoxifen-resistant cells derived from T47D (TAMRT) cells were treated with increasing Tam doses for 72 hours. Proliferation was determined and
normalized to respective untreated controls. For graphs, averages are presented with error bars indicating the standard error of the mean. Asterisk (*)
indicates significant difference (P value < 0.05), compared to control group. Dt, doubling time.
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target gene expression and proliferation of ER-positive
MCF7 cells. To determine the role of the ER in the ac-
celerated growth rate of TAMRM cells, we conducted
siRNA-mediated knockdown of ER (ESR1) mRNA in
both MCF7 and TAMRM cells, and found comparableER depletion resulted in an approximately 60% growth
reduction in both cell lines (Figure 3A). This suggests
the ER remains an important mediator of cell growth in
TAMRM cells despite substantial reduction in sensitivity
to estrogen and anti-estrogens (Figure 1). We next tested
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Figure 2 Tamoxifen-resistant cells display altered gene expression profile. (A) MCF7 and tamoxifen-resistant cells derived from MCF7
(TAMRM) basal mRNA levels of ESR1, BCL-2, c-MYC, PGR and TFF1 are represented normalized to h.glucoronidase. (B) Comparison of estrogen
receptor (ER), Bcl-2, c-Myc and p21 baseline expression in MCF7 and TAMRM by western blot. As a suitable loading control protein could not be
identified, the Ponceau S stained membrane is presented to demonstrate equal protein loading. Bands were quantified by densitometry. The
value below each band represents quantified protein in respective cell line normalized to MCF7. (C) Western blot analysis of ER, Bcl-2, c-Myc and
p21 expression levels in untreated MCF7 and TAMRM tumor xenografts are presented. Comparison of T47D and tamoxifen-resistant cells derived
from T47D (TAMRT) basal levels of ER, progesterone receptor (PGR) and Bcl-2 protein (D) and mRNA (E) are presented where protein expression is
normalized to GAPDH, while mRNA expression is normalized to h. glucoronidase. ImageJ software was used for densitometry analysis of western
blots. For graphs, averages are presented with error bars indicating the standard error of the mean.
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vity of the ER in TAMRM and MCF7 cells, we transfected
each with a luciferase reporter plasmid (pERE-luc-tk)
driven by a promoter containing an ERE. As expected,
treatment of MCF7 cells with E2 increased luciferase ac-
tivity with increasing dose, while Tam and Ful decreased
luciferase activity below basal levels. On the other hand,
luciferase activity in TAMRM cells remained unaffected by
E2 or anti-estrogen treatment (Figure 3B). To evaluate
whether the ER-mediated target gene transcription wasaltered in TAMRM cells, mRNA from a set of known ER-
responsive genes (for example PGR, TFF1, CDH1, c-MYC,
H.CTSD, GREB1, TRIM25, and BCL2), were quantified
following siRNA-mediated depletion of the ER and com-
pared to similar depletion in MCF7 cells (Figure 3C). In
MCF7 cells, ER depletion resulted in downregulation of
all target mRNAs to varying degrees. Interestingly in
TAMRM cells, all but three transcripts (for example TFF1,
CDH1 and c-MYC) were downregulated following ER de-
pletion, suggesting that, independent of E2, ER continued
Figure 3 ER-mediated transactivation and ligand sensitivity is altered in TAMRM cells. (A) MCF7 and tamoxifen-resistant cells derived from
MCF7 (TAMRM) cells were transfected with ESR1-directed small interfering RNA (siRNA) or scramble and total cell count was monitored after 5 days.
Western blot of ER knockdown is presented. (B) MCF7 and TAMRM cells were transfected with an ERE-tk-luc plasmid and treated with either
vehicle (DMSO); 0.01 or 0.1 nM estradiol (E2); 10 or 100 nM 4-hydroxy tamoxifen (Tam); 10 or 100 nM fulvestrant (Ful) for 20 hours and assayed
for luciferase activity (C) MCF7 and TAMRM cells were transfected with ESR1-directed siRNA and assayed for mRNA expression of estrogen receptor (ER)
target genes. mRNA expression is normalized to scramble control for each cell line. (D) MCF7 and TAMRM cells were incubated in phenol red-free
media supplemented with 5% charcoal dextran stripped serum (CDSS) for 72 hours after which 0 nM or 0.1 nM E2 was added for 24 hours and mRNA
expression of depicted genes was quantified and represented as fold change upon E2 stimulation versus no E2. For graphs, averages are presented
with error bars indicating the standard error of the mean.
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whether ER-mediated expression was truly E2 independ-
ent, TAMRM cells were stimulated with E2 and mRNA
levels of these select genes were quantified and compared
to MCF7 cells (Figure 3D). Consistent with siRNA-
mediated depletion of ER, E2 stimulation did not sig-nificantly increase TFF1 and CDH1 mRNA, while c-MYC,
H.CTSD and BCL-2 mRNA were only slightly increased.
PGR and GREB1 mRNA were significantly increased with
E2 stimulation; however, their increase was substantially
less than the increase observed in MCF7 cells. Taken to-
gether, these results suggest that ER remains important
Raha et al. Breast Cancer Research  (2015) 17:26 Page 8 of 16for TAMRM cell growth, but has differential transactiva-
tion properties at target genes compared to MCF7 cells.
Furthermore, the ER in TAMRM cells has significantly re-
duced sensitivity to E2.
Combined HDAC and ER inhibition reduces proliferation
and viability of tamoxifen-resistant cells
We have previously shown that the addition of an
HDAC inhibitor to hormonal therapy can induce apop-
tosis in breast cancer cells and reverse hormone therapy
resistance in clinical studies [11,26,27]. For this study,
the potent hydroxamic-type pan-HDAC inhibitor PCI-
24781 (abexinostat) was primarily used. To evaluate the
efficacy of this combination, TAMRM cells were treated
with increasing concentrations of PCI, with and without
10 μM Tam, and assayed for viability after 72 hours
(Figure 4A). At clinically feasible concentration of PCI
(200 nM), combination with Tam resulted in cell death
in about 54% of the TAMRM cells, greater than the addi-
tive effect of either agent alone. The PT drug combi-
nation was most effective in inhibiting colony formation.
(Figure 4B). Consistent with an elevated proliferation
rate (Figure 1A), untreated TAMRM cells formed co-
lonies within 14 days, while MCF7 cells failed to form
detectable colonies within this time (DNS).
In MCF7 cells, combined HDAC and ER inhibition re-
sults in reduced proliferation, with cells accumulating in
G1 of the cell cycle. As such, the effect of PCI and Tam
alone and in combination on cell cycle progression after
24-hour treatment was examined. Untreated TAMRM
cells had a 2-fold greater G2-M population (Figure 4C)
compared to parental MCF7 cells, consistent with acce-
lerated growth. Unlike in MCF7 cells, Tam treatment did
not result in a G1 shift in the TAMRM cells. Treatment
with PCI, however, resulted in a similar G1 accumula-
tion for both TAMRM and MCF7 cells. When treated in
combination, both MCF7 and TAMRM cells exhibited
cell cycle distributions comparable to PCI treatment
alone. We next evaluated the effect of the PT combin-
ation on cell proliferation after 72 hours of treatment.
PCI alone comparably restricted growth of both cell
lines. While Tam alone significantly reduced the growth of
parental cells (80%), it only modestly reduced TAMRM cell
growth (30%) (Figure 4D). The combination treatment re-
sulted in an enhanced anti-proliferative effect, comparable
in both cell lines. The combined effect of HDAC and ER
inhibition on TAMRM cell viability was not limited to
PCI. Combinations with Tam and several other HDAC in-
hibitors, including valproic acid, panobinostat, entinostat
and vorinostat, resulted in a greater than additive reduc-
tion in cell viability (Figure 4E). To exclude the possibility
of any non-ER mediated effect of Tam we have demon-
strated enhanced apoptotic cell death by HDAC inhibition
in ER-depleted TAMRM cells (Figure S2 in Additionalfile 2). We further evaluated whether treatment with PCI
and Tam could induce cell death in TAMRT cells. After
72 hours of treatment, PCI alone induced 30% cell death,
Tam alone did not lead to significant death, and the
combination resulted in 60% cell death, suggesting an en-
hanced effect in presence of both drugs (Figure 4F). In
summary, combined HDAC and ER inhibition induced
growth arrest and cell death in our acquired Tam-resistant
breast cancer models. While growth arrest appeared to be
primarily the effect of HDAC inhibition, significant cell
death required both agents.
Combined HDAC and ER inhibition reverses altered Bcl-2,
c-Myc and p21 expression
As shown in Figure 2, the major anti-apoptotic protein,
Bcl-2, and proliferation driver, c-Myc, are significantly
overexpressed in TAMRM cells. Additionally, a key cell
cycle break, p21, is downregulated. We thus hypothesized
that the efficacy of combined HDAC and ER inhibition
may be the result of reversing the altered expression of
these key proteins. To test this hypothesis, we first treated
TAMRM cells with increasing concentrations of PCI for
24 hours and evaluated protein expression of ER, p21,
c-Myc, and Bcl-2 (Figure 5A). With increasing dose, ER
and c-Myc protein were significantly downregulated, while
p21 was upregulated. Although modest, Bcl-2 protein was
reproducibly reduced when treated with 100 nM or more
PCI. As HDACs regulate both ER protein stability and
transcription, the effect of PCI treatment on ER mRNA
was evaluated. As seen previously with MCF7 cells,
HDAC inhibition using PCI reduced TAMRM cell tran-
scription of ER mRNA in a dose- and time-dependent
manner (Figure S3 in Additional file 3). To determine the
effect of combined HDAC and ER inhibition on the ex-
pression of these key proteins, MCF7 and TAMRM cells
were treated with vehicle, 200 nM PCI, 10 μM Tam, or
the combination for 48 hours and evaluated for c-Myc,
p21, and Bcl-2 expression (Figure 5B). In MCF7 cells,
treatment with either single agent reduced c-Myc and
Bcl-2 and increased p21 expression. In TAMRM cells, PCI
elicited similar changes to the expression of these proteins
compared to MCF7 cells, while Tam had no effect on p21
or c-Myc expression, but slightly reduced Bcl-2. PCI treat-
ment reduced ER in both cell lines. Though Tam treat-
ment stabilized ER in MCF7 cells, ER was unaltered in
TAMRM cells. With the PT combination, p21 expression
was further increased in MCF7 cells compared to single
agent treatment. Due to the significant single agent effect
on c-Myc and Bcl-2 expression, a combination effect was
difficult to determine in MCF7 cells. In TAMRM cells,
combination treatment resulted in similar changes to ER,
p21 and c-Myc expression compared to PCI treatment
alone. In contrast, PT combination resulted in a greater
than additive decrease in Bcl-2 expression.
Figure 4 Combined HDAC and ER inhibition reduces proliferation and viability of tamoxifen-resistant cells. (A) Tamoxifen-resistant cells
derived from MCF7 (TAMRM) cells were treated with and without 10 μM 4-hydroxy tamoxifen (Tam) and increasing concentrations of PCI-24781
(PCI) for 72 hours and assayed for viability using a trypan blue dye exclusion assay. (B) TAMRM cells were treated with either vehicle (C), 200 nM
PCI (P), 10 μM Tam (T) or the combination of PCI-24781 and 4-hydroxy tamoxifen (PT) for 72 hours and evaluated by colony formation assay.
Colonies were counted after 2 weeks and considered formed if they contained approximately >100 cells. MCF7 and TAMRM cells were treated with
vehicle (C), 200 nM PCI (P), 10 μM Tam (T) or the combination (PT) for (C) 24 hours and evaluated for cell cycle composition by flow cytometry or
(D) 72 hours and evaluated for relative proliferation by MTS assay. (E) TAMRM cells were treated with either 0.5 mM valproic acid, 25 nM panobinostat,
1 μM vorinostat or 1 μM entinostat in presence and absence of 10 μM Tam for 72 hours and assayed for viable cells. (F) T47D and tamoxifen-resistant
cells derived from T47D (TAMRT) cells were treated as in (D) and assayed for viable cells. Asterisk (*) indicates significant difference (P value <0.05)
whereas (#) indicates insignificant difference (P value >0.05), compared to control group. HDAC, histone deacetylase.
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(Figure 3C) similar to that observed in parental MCF7
cells [23]. Depletion of ER using increasing concentra-
tions of ESR1-directed siRNA (Figure 5C) resulted in acommensurate decrease of BCL-2 mRNA in the resistant
cells, demonstrating that the ER continues to regulate
BCL-2 transcription. However, physiological levels of E2
(0.1 nM) or E2 + Tam (0.1 nM E2 and 10 μM Tam) fail
Figure 5 Combined HDAC and ER inhibition reverses altered Bcl-2, c-Myc, and p21 expression. (A) Tamoxifen-resistant cells derived from
MCF7 (TAMRM) cells were treated with increasing concentrations of PCI-24781 (PCI) for 24 hours and evaluated for estrogen receptor (ER), p21,
c-Myc, Bcl-2 and GAPDH expression by western blot. (B) MCF7 and TAMRM cells were treated with vehicle (C), 200 nM PCI (P), 10 μM 4-hydroxy
tamoxifen (Tam) (T), or the combination of PCI-24781 and 4-hydroxy tamoxifen (PT) for 48 hours and evaluated for ER, c-Myc, p21 and Bcl-2
expression by Western blot. (C) TAMRM cells were transfected with increasing concentrations of small interfering RNA (siRNA) for ESR1 and
24 hours later analyzed for BCL-2 expression. The blot depicts loss of ER protein with increasing concentrations of siRNA directed to ER. MCF7
and TAMRM cells were incubated in estrogen-free media for 48 hours and (D) treated with vehicle (DMSO) (C), 0.1 nM estradiol (E2) or 0.1 nM E2 + 10 μM
Tam for 24 hours and (E) TAMRM cells were treated with increasing doses of E2 (0.1, 1 or 10 nM) in presence or absence of 200 nM PCI for 24 hours
and relative BCL-2 mRNA expression was measured. (F) Relative BCL-2 mRNA expression was measured in complete media 24 hours post treatment
with vehicle (C), 10 μM Tam, 200 nM PCI, 2 mM valproic acid or 20 nM panobinostat, in absence and presence of Tam. Asterisk (*) indicates significant
difference (P value <0.05) whereas (#) indicates insignificant difference (P value >0.05), compared to control group. HDAC, histone deacetylase.
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contrast to MCF7 cells (Figure 5D). To find out whether
this was due to reduced sensitivity of the ER to ligands,
TAMRM cells were treated with increasing concentra-
tions (0.1, 1 and 10 nM) of E2. A statistically significant
increase in BCL-2 mRNA was observed with only 10nM E2, but not with lower E2 doses (Figure 5E). To
examine the influence of PCI on the ER response to E2,
BCL-2 mRNA was evaluated in the presence of 200 nM
PCI and increasing E2 doses. PCI (200 nM) slightly re-
duced BCL-2 mRNA, potentially by downregulating ER
expression, which was significantly reversed with the
Figure 6 PCI and Tam combination alters expression of
pro-apoptotic proteins and promotes apoptosis. (A) Tamoxifen-
resistant cells derived from MCF7 (TAMRM) cells were treated with
increasing doses of PCI-24781 (PCI) for 72 hours and expression of
indicated proteins were evaluated by western blot. (B) MCF7 and
TAMRM cells were treated with vehicle (C), 200 nM PCI (P), 10 μM
4-hydroxy tamoxifen (Tam) (T) or the combination of PCI-24781 and
4-hydroxy tamoxifen (PT) for 72 hours and PARP cleavage and
expression of pro-apoptotic proteins was evaluated by western blot.
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This suggested that the ER in TAMRM cells are less sen-
sitive to E2 and require more E2 to modulate expression
of BCL-2. To evaluate whether HDAC inhibition en-
abled Tam to reduce ER-mediated BCL-2 transcription,
TAMRM cells were treated with DMSO (C), 10 μM Tam,
200 nM PCI or PT for 24 hours and BCL-2 mRNA ex-
pression was determined (Figure 5F). Tam alone had no
significant effect on BCL-2 mRNA. Treatment with PCI
reduced BCL-2 mRNA modestly (approximately 30%),
even though the ER was reduced by approximately 75%
at this dose. Higher concentrations of PCI, beyond the
clinically feasible dose of 200 nM, did significantly de-
plete BCL-2 mRNA (Figure S4 in Additional file 4), con-
sistent with the increased rates of cell death at those
doses. However, combined PT treatment reduced BCL-2
mRNA levels by approximately 70% (Figure 5F). To de-
termine whether these effects were specific to PCI, other
HDAC inhibitors, valproic acid (2 mM) and panobino-
stat (20 nM) were evaluated. Both inhibitors alone did
not significantly decrease BCL-2 mRNA, however, in
combination with Tam, BCL-2 mRNA was significantly
reduced.
PCI and Tam combination alters expression of
pro-apoptotic proteins and promotes apoptosis
The combination of HDAC and ER inhibition causes cell
death in MCF7 and TAMRM cells (Figure 4). HDAC in-
hibitors are known to induce pro-apoptotic proteins,
which we have previously shown with PCI-treated
MCF7 cells [13]. Thus, we hypothesized that downregu-
lation of Bcl-2 (Figure 5) combined with upregulation of
pro-apoptotic factors together drive TAMRM cells into
apoptosis. To test this hypothesis, TAMRM cells were
treated with increasing concentrations of PCI for 72 hours
and evaluated for expression changes in key apoptotic
proteins (Figure 6A). In response to increasing PCI doses,
several pro-apoptotic proteins, including Bax, Bak, Bok
and cleavage of Bid, exhibited pro-apoptotic expression
changes accompanied by a modest increase in PARP
cleavage. To evaluate the effect of combined HDAC and
ER inhibition on the expression of these proteins and the
induction of apoptosis, MCF7 and TAMRM cells were
treated with 200 nM PCI (P), 10 μM Tam (T), or the com-
bination for 72 hours. Changes to apoptotic proteins in
both MCF7 and TAMRM cells were primarily seen with
PCI treatment and not Tam, with the combination treat-
ment eliciting similar changes to PCI treatment alone
(Figure 6B). An exception seen in both MCF7 and
TAMRM cells was Bax expression, which exhibited a grea-
ter than additive increase. Furthermore PARP cleavage
was significantly enhanced in both cell lines with PT com-
bination, confirming apoptotic cell death. Taken together
these results suggest that HDAC inhibition can reverseTam resistance by depletion of the major pro-survival
protein Bcl-2 and upregulation of pro-apoptotic factors,
driving cells into apoptosis.
Causal interaction of HDAC and BCL-2 in survival of
TAMRM cells
Several studies have demonstrated that overexpression
of the pro-survival protein Bcl-2 confers resistance to
apoptosis by apoptotic inducers in several cancers, in-
cluding breast [28-30]. Similarly, apoptosis induction in
TAMRM was much lower compared to MCF7 cells when
challenged with increasing doses of the apoptotic stress
inducers, Tam or the anthracycline doxorubicin (Figure S5
in Additional file 5). To establish Bcl-2 as a major con-
tributor to apoptotic resistance in TAMRM cells, the Bcl-2
family member inhibitor ABT.263 was employed. Treat-
ment of TAMRM cells with doses of ABT.263 up to
10 μM resulted in modest PARP cleavage (Figure 7A),
consistent with previous reports that demonstrate similar
inhibitors alone are insufficient to induce apoptosis in
breast cancer cells [31]. However, when combined with
PCI (200 nM), 1 μM ABT.263 was sufficient to substan-
tially induce PARP cleavage and cell death in TAMRM
cells (Figure 7A and B). Furthermore, combined ABT.263
and PCI treatment resulted in cell death comparable to
combined Tam and PCI treatment in both MCF7 and
TAMRM cells (Figure 7B). To specifically implicate Bcl-2
as the key target, Bcl-2 was first depleted in TAMRM cells.
Analysis of mRNA expression revealed about 50% tran-
sient knockdown of BCL-2 mRNA (Figure 7C). These
cells were then treated with PCI for 72 hours. Combined
Bcl-2 depletion and HDAC inhibition was sufficient to in-
duce significant cell death in TAMRM cells (Figure 7D).
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Figure 7 Causal interaction of HDAC and BCL-2 in survival of TAMRM cells. (A) Tamoxifen-resistant cells derived from MCF7 (TAMRM) cells
were treated with increasing doses of ABT.263 in presence of 200 nM PCI-24781 (PCI) or increasing doses of PCI in presence of 1 μM ABT.263 and
assayed by western blot for PARP cleavage. (B) MCF7 and TAMRM cells were treated with vehicle (C), 200 nM PCI, 1 μM ABT.263 or the combination for
96 hours and analyzed for cell death. (C) MCF7 and TAMRM cells were transfected with either scramble or a Bcl-2-specific small interfering RNA (siRNA)
and extent of knockdown is represented by BCL-2 mRNA levels. (D) Treatment of the transient BCL-2 knockdown MCF7 and TAMRM cells were treated
with 200 nM PCI for 72 hours and analyzed for cell death and PARP cleavage. Asterisk (*) indicates significant difference (P value <0.05) whereas (#)
indicates insignificant difference (P value >0.05) compared to control group. HDAC, histone deacetylase.
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followed by PCI treatment did not lead to additional cell
death compared to PCI treatment alone. Together, these
results demonstrate that Bcl-2 and HDAC inhibition is
sufficient to induce cell death in TAMRM cells.
Discussion
The emergence of Tam resistance is almost inevitable in
breast cancer. To aid in the development of novel thera-
peutics for this space, we generated breast cancer cell
line models with substantially decreased sensitivity to
Tam. Here we report Tam-resistant cell lines that main-
tain ER expression, but lose PGR expression. This receptor
status is often seen in breast tumors and is associated
with a relatively poor outcome. Our Tam-resistant breast
cancer models exhibit ligand-independent growth and
altered ER-mediated genomic signaling. We demonstrate
that the ER is directly involved in controlling the pro-
survival protein Bcl-2 by modulating its transcript. Our
data further show that the addition of an HDACinhibitor to the anti-estrogen Tam leads to inhibition of
proliferation, prevention of colony formation, and in-
duction of apoptotic cell death by downregulating Bcl-2
and upregulating pro-apoptotic proteins. HDAC inhib-
ition in the presence of Tam results in depletion of ER
and Bcl-2. As these effects are mimicked by genetically or
pharmacologically silencing Bcl-2, we conclude that the
HDAC inhibitor-mediated induction of several apoptotic
proteins and reversal of Bcl-2 upregulation through ER
ensues cell death in our Tam-resistant cells. Though ap-
parently high, the dose of 10 μM Tam used in our studies
is justified based on the fact that the experimental media
contains phenol red with pro-estrogenic properties, hence
reducing Tam’s effective dose. Moreover, clinical trials in
patients with high-dose Tam have reported approximately
3 to 4 μM plasma levels of Tam achieved without dose-
limiting toxicity [32,33]. We recognize the limitation of
not using a parallel passaged MCF7 control for this study.
In TAMRM cells, we demonstrate that ERE-mediated
transactivation is altered and that the ER has become less
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ER response genes PGR and TFF1 are substantially re-
duced in our model, consistent with previous findings
[16,17,34]. As with the MCF7-derived TAMRM cells, the
T47D-derived TAMRT cells also maintain ER expression,
while losing PGR expression. The maintenance of ER ex-
pression following acquired resistance to anti-estrogens is
consistent with breast tumors, as most retain ER ex-
pression (approximately 70 to 75%) [21,22,35]. The sup-
pression of classic ER-response genes, PGR and TFF1, and
lower basal luciferase activity at externally transfected ERE
sites suggested reduced ER activity in TAMRM cells des-
pite elevated ER expression. Nonetheless, ER-mediated
genomic signaling was not suppressed, but redirected,
compared to MCF7 cells. A similar alteration of the ER
transcriptome through a post translationally modified ER
has been demonstrated recently by de Leeuw et al. [36].
Interestingly, the ER retained its transactivation function
at most target genes that we evaluated. Furthermore,
both TAMRM and TAMRT cells exhibited elevated BCL-2
mRNA and protein. However, despite the c-MYC onco-
gene being elevated in TAMRM cells, ER did not regulate
its transcription in contrast to MCF7 cells [37]. Our re-
sults show that ER is necessary for the proliferation of re-
sistant cells signifying the retained importance of the ER
in driving growth of these cells. Since recent studies sug-
gest that mutations in the ligand-binding domain of ER
may play an important role in the emergence of hormonal
therapy resistance, we tested the possibility of point muta-
tions in the ER in our resistant cells, by sequencing the
entire gene, but found none [38].
ER-HDAC crosstalk and modulation of both ER
expression and stability by HDAC inhibitors has been
reported [26,39]. We demonstrate that the HDAC in-
hibitor, PCI, efficiently reduces ER mRNA and protein in
ER-positive TAMRM cells. We speculate this reduction is
through similar mechanisms reported by other groups
including pan-HDAC inhibitor-mediated induction of
transcriptional repressor proteins, local methylation of
CpG islands, influence on ER mRNA stability or through
Hsp90 hyperacetylation resulting in loss of ER protein
stability [40-42]. To the contrary, HDAC inhibition in
ER-negative breast cancer cells, however, induces ER
expression either through reversal of promoter hyperme-
thylation or de-repression of ER mRNA via hyperacti-
vated MAPK [43,44]. Previous studies have shown that
HDAC inhibition induces expression of CDK inhibitors,
such as p21, which causes cell cycle arrest in breast car-
cinomas [45,46]. PCI treatment similarly increases the
CDK inhibitor p21 and causes G1 arrest in our resistant
cells. Furthermore, HDAC inhibition also downregulates
the elevated c-Myc in the TAMRM cells. Thus, HDAC
inhibitor-mediated epigenetic modulation reduces proli-
feration in TAMRM cells.Tumors employ diverse means to evade apoptosis, in-
cluding modulation of Bcl-2 [47]. ER induces transcription
of Bcl-2 in breast cancer cells upon estrogen stimulation
[23]. In several clinical studies, increased Bcl-2 expression
in breast tumors has correlated with favorable response to
endocrine therapy [48,49]. Johnston et al. have reported
that Tam treatment resulted in increased Bcl-2 expression
in breast tumors, which, however, correlated with reduced
Ki67 index or decreased cell proliferation [50]. Planas-Silva
et al. analyzed tumor samples following progression on ad-
juvant hormonal therapy and reported increased Bcl-2 and
c-Myc expression in metastatic lesions, compared to the
primary tumor. In contrast to this finding, Gutierrez et al.
analyzed tumors biopsied from local relapses while still on
hormonal therapy and reported no increase in Bcl-2 ex-
pression upon tamoxifen treatment failure. Furthermore,
the positive correlation between ER and Bcl-2 in primary
tumors was lost following progression on hormonal the-
rapy [51,52]. These clinical studies illustrate the complexity
regarding Bcl-2 expression and hormonal therapy resis-
tance. Although both directly compared Bcl-2 levels in the
primary tumor and in tumors following hormonal therapy
failure, they differed in terms of the site of recurrence, local
versus distal metastasis. Furthermore, in one study, tumors
were collected post endocrine treatment, whereas the other
study was during continuation of Tam therapy, leading to
the possibility of ER-dependent or ER-independent modu-
lation of Bcl-2. Our Tam-resistant models exhibit Bcl-2
upregulation and maintenance of a positive correlation be-
tween ER and Bcl-2 post resistance, similar to the Planas-
Silva study, suggesting Bcl-2 upregulation is an important
phenomenon in metastatic Tam-resistant tumors. Further,
we demonstrate the causal role for Bcl-2 upregulation in
hormone therapy resistance, as its direct inhibition by an
HDAC inhibitor PCI and Tam via the ER induces apop-
tosis, emphasizing the relevance of inhibiting both Bcl-2
and HDACs. Although very high levels of E2 can stimulate
BCL-2 transactivation through the ER, premenopausal
levels of E2 have a negligible effect on BCL-2 expression.
This is in contrast to the significant increase in BCL-2
expression elicited by E2 in MCF7 cells. This further de-
monstrates the reduced sensitivity of ER to ligands in the
Tam-resistant cells.
We have previously reported that co-administration of
the HDAC inhibitor valproic acid and Tam, in Tam-
sensitive T47D cells, leads to depletion of Bcl-2 protein
[27]. From results in the current study, we conclude that
the reduction of Bcl-2 mRNA by HDAC inhibition alone
is modest, but when combined with Tam, its expression
is significantly downregulated. We show that HDAC
inhibition results in ER loss leading to decreased Bcl-2
expression. We speculate that tamoxifen further blocks
residual ER activity at Bcl-2 promoter strongly eli-
minating Bcl-2 protein. However, studies detailing the
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this therapeutic combination are ongoing.
The ability of PCI to induce cell death in Tam-
resistant cells when Bcl-2 activity is repressed either
genetically or pharmacologically emphasizes the impor-
tance of Bcl-2 as a target in Tam resistance. Recent
studies of Bcl-2-specific inhibitors, in both in vitro
models as well as in primary breast tumor xenografts
that overexpress Bcl-2, have shown they potentiate
apoptosis when combined with Tam [31]. Our data pro-
vides compelling evidence that HDAC inhibitors should
be used in combination with Tam or a Bcl-2-specific in-
hibitor against tumors with elevated Bcl-2. Since ER
drives resistance through modulation of Bcl-2, contin-
ued suppression of ER-mediated transactivation is likely
important. The amount of cell death induced in MCF7
cells by co-administration of ABT.263 and PCI is similar
to that in TAMRM cells (Figure 7B), raising the possi-
bility that targeting Bcl-2 and HDACs may also be an
effective approach against tumors that do not exhibit el-
evated Bcl-2. As Bcl-2 is a key gatekeeper, countering
apoptotic induction, it is not surprising that inhibiting it
(for example pharmacologically or genetically) in the
Tam-sensitive and -resistant cells tips the balance of
both toward apoptosis when combined with the pro-
apoptotic effects of HDAC inhibition. However, in this
context, the effectiveness in both MCF7 and TAMRM
cells may be attributed to ABT.263’s ability to target
Bcl-2 and its family members, Bcl-xl and Bcl-w, and by
inhibiting the complete family, apoptosis may be in-
duced irrespective of differing Bcl-2 levels. In support of
this explanation, siRNA-mediated depletion of Bcl-2 en-
hanced apoptosis, when combined with PCI, only in the
BCL-2-overexpressed TAMRM cells (Figure 7C), but not
in the MCF7 cells.Conclusions
The TAMRM and TAMRT cells represent a novel model
of Tam-resistant ER-positive/PGR-negative breast cancer
that exhibits elevated ER and Bcl-2 expression. This
study emphasizes the importance of Bcl-2 elevation in
acquired Tam resistance. It demonstrates that Bcl-2
downregulation and induction of pro-apoptotic proteins
by combined ER and HDAC inhibition leads to apop-
totic cell death of Tam-resistant cells. Inhibition of ER
alone is sufficient to reduce growth, but not achieve cell
death. Combined HDAC and ER inhibition inhibits pro-
liferation and induces apoptosis by reversing changes to
p21, c-Myc, and Bcl-2 expression and inducing pro-
apoptotic factors. Thus, this work suggests that adding
an HDAC inhibitor to anti-estrogen therapy may be ef-
fective in treating Tam-resistant ER-positive disease with
elevated Bcl-2 expression.Additional files
Additional file 1: Figure S1. TAMRM cells form tumors in mice in
absence of an estradiol pellet. TAMRM cells were grown in phenol
red-free media supplemented with charcoal dextran stripped serum for
7 days before implanting subcutaneously in two mice for tumor formation.
Tumor growth in absence of estradiol pellet was evaluated over time by
caliper measurement and calculating volume as 0.5 (tumor length x tumor
width2).
Additional file 2: Figure S2. PCI-24781 induces cell death in TAMRM
cells genetically silenced for ER. TAMRM cells were transfected with
ESR1-directed siRNA and subsequently treated with PCI-24781 for 72 hours.
Cells were then evaluated for viability (A) and PARP cleavage (B).
Additional file 3: Figure S3. The HDAC inhibitor PCI-24781 negatively
regulates ER mRNA. TAMRM cells were treated with either (A) increasing
concentrations of the HDAC inhibitor PCI-24781 for 24 hours or (B) with
200 nM of PCI-24781 for 0, 2, 4, 10 and 24 hours, after which ER mRNA
expression was evaluated.
Additional file 4: Figure S4. PCI-24781 reduces BCL-2 mRNA in a
dose-dependent manner. TAMRM cells were treated with increasing
concentrations of PCI-24781 (0, 200, 400, 800 nM) for 24 hours and BCL-2
mRNA expression was evaluated.
Additional file 5: Figure S5. TAMRM cells exhibit decreased sensitivity
to apoptotic stress compared to MCF7 cells. MCF7 and TAMRM cells were
treated with increasing concentrations of (A) Tam and (B) doxorubicin for
72 hours and evaluated for cell death by trypan blue dye exclusion assay.
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